Entera Bio Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTX Nasdaq 2836 enterabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entera Bio Ltd.

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation - May 28th, 2026 6:50 am
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs - May 8th, 2026 2:05 pm
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know - Apr 29th, 2026 10:00 am
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near - Apr 24th, 2026 5:33 pm
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity - Apr 20th, 2026 9:59 am
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 - Apr 14th, 2026 6:45 am
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds - Apr 2nd, 2026 6:45 am
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - Mar 27th, 2026 2:05 pm
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Mar 4th, 2026 6:30 am
Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board - Feb 27th, 2026 5:00 am
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference - Feb 26th, 2026 6:00 am
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Feb 17th, 2026 6:42 pm
Entera Bio Announces Open Market Purchases of Company Stock by Board Members - Feb 11th, 2026 7:00 am
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - Feb 9th, 2026 6:50 am
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Feb 6th, 2026 9:02 am
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - Feb 4th, 2026 6:00 am
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook - Jan 21st, 2026 6:30 am
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation - Dec 31st, 2025 5:51 am
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - Dec 23rd, 2025 6:30 am
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - Dec 22nd, 2025 6:30 am